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The evolution of antibiotic resistance is a major threat to
society and has been predicted to lead to 10 million casualties
annually by 20501. Further aggravating the problem, multidrug
tolerance in bacteria not only relies on the build-up of resist-
ance mutations, but also on some cells epigenetically switching
to a non–growing antibiotic-tolerant ‘persister’ state2–6. Yet,
despite its importance, we know little of how persistence
evolves in the face of antibiotic treatment7. Our evolution exper-
iments in Escherichia coli demonstrate that extremely high levels
of multidrug tolerance (20–100%) are achieved by single point
mutations in one of several genes and readily emerge under con-
ditions approximating clinical, once-daily dosing schemes. In
contrast, reversion to low persistence in the absence of antibiotic
treatment is relatively slow and only partially effective.
Moreover, and in support of previous mathematical models8–10,
we show that bacterial persistence quickly adapts to drug treat-
ment frequency and that the observed rates of switching to the
persister state can be understood in the context of ‘bet-hedging’
theory. We conclude that persistence is a major component of
the evolutionary response to antibiotics that urgently needs to
be considered in both diagnostic testing and treatment design
in the battle against multidrug tolerance.
Bacteria rely on diverse strategies to survive changing and stress-
ful environments. One such strategy is risk-spreading or ‘bet-
hedging’11, in which populations invest in phenotypic variants
that are pre-adapted to future environments but maladapted to
the present environment12. A prime example in bacteria is persist-
ence, in which a fraction of all cells (usually 0.0001–0.1%)13
makes a phenotypic switch from a sensitive to a non-growing anti-
biotic-tolerant state2,6, thereby trading instantaneous growth for
long-term survival2,8. Clearly, persistence should be a cause of
global concern, as it aggravates the outlook of the ongoing antibiotic
crisis, which has been estimated to lead to as many as 10 million
casualties annually by 20501. Unlike antibiotic-resistant mutants,
persisters are undetectable with routine clinical tests and are geneti-
cally indistinguishable from the non-persister part of the popu-
lation3. Worryingly enough, persistence has been reported in
virtually all major bacterial pathogens, from Staphylococcus aureus
to Mycobacterium tuberculosis, and is held responsible for the
chronic and sometimes incurable nature of many infections4.
Yet, despite its clinical importance, little is known about the
evolutionary forces that shape this phenotype7. Evolutionary
theory on ‘bet-hedging’ predicts that persister levels should directly
correlate with prevailing antibiotic treatment frequencies2,8–10,14,
which could be of paramount clinical importance if correct.
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Figure 1 | Frequent antibiotic exposure leads to the fast emergence of high
survival levels. a, Set-up of evolution experiment with antibiotic treatments.
Every round, stationary–phase cultures were treated with antibiotics and
surviving cells were grown overnight in fresh medium. In experiments with
altered treatment frequencies (Figs 3 and 4), cultures were diluted in fresh
medium on days without treatment (grey arrow). b, Evolution of survival
fraction of parallel isogenic populations exposed daily to amikacin (red),
kanamycin (purple), tobramycin (blue) and gentamicin (green) resulted in
a rapid increase in survival (mean ± s.e.m., n≥ 9 with sigmoidal fit and
95% c.i. (shading) expected for the spread of a mutant in a haploid population,
see equations 1–3 in Supplementary Methods). Significance of difference
between starting value: *P <0.05, ***P <0.001, for the first round where it was
observed (repeated measures ANOVA with Dunnett post-hoc correction).
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Indeed, frequent antibiotic exposure has been held to be responsible
for the increase in persistence levels in vivo15, and has resulted in
selection for population-wide tolerance under laboratory con-
ditions16. Yet, the detailed evolutionary dynamics of persistence
remain largely unexplored. Critically, it is unknown how fast persist-
ence adapts to prevailing antibiotic treatment frequencies and how
easily high persistence can be reverted. Here we use the model
organism E. coli and in vitro experimental evolution to tackle
these important outstanding questions.
In our first experiment, we tested how fast persistence evolves in
response to daily antibiotic treatments (Fig. 1a). Theory predicts
that under such frequent antibiotic treatment regimens, persister
levels of up to 100% could ensue8–10. In support, we found that
when we exposed ten replicate E. coli populations to daily amikacin
antibiotic treatments, all populations quickly adapted in a highly
reproducible way and increased their survival level ∼300-fold,
from 0.17% initially, to 20–100% from the third treatment round
onwards (Fig. 1b). Furthermore, in experiments using other amino-
glycoside antibiotics, tolerance increased to a similar extent, by
around 3 orders of magnitude, showing that this response is
generic (Fig. 1b). However, survival levels at the end of the evolution
experiments differed slightly between antibiotics — possibly as a
result of varying evolutionary constraints. As amikacin tolerance
appeared to be least constrained, ultimately reaching the highest sur-
vival levels, we focussed on this antibiotic in our subsequent exper-
iments. By picking random clones from the end of our evolution
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Figure 2 | Single mutations in evolved clones cause multidrug tolerance, not by increased antibiotic resistance but by increased persistence. a,b, Amikacin
(a) and ofloxacin (b) killing curves in function of time for 11 clones collected from various populations at the endpoint of the evolution experiment under
daily amikacin treatment (red; Fig. 1b) and the ancestor (grey) demonstrate increased persistence (mean ± s.e.m., n≥ 3 with the per treatment biphasic fit
(thick lines) expected for the killing of a population containing a subpopulation of normal and persister cells, see Supplementary Methods). c,d, MIC–strips
applied to the ancestor (grey outlines) and three evolved clones of which the whole genome was sequenced (red-outlines; see text and Supplementary
Table 1) demonstrate that MICs (red lines) for amikacin (c) and ofloxacin (d) remained unchanged in the evolved clones relative to their ancestors
(respectively 1 and 0.023 µg ml−1, representative strips of n = 2 are shown). e,f, Repairing the point mutation present in each of these three high-persistence
mutants (mutant*) to the ancestral allele (mutant*repair) resulted in a complete reversal from high-persistence to the low levels of persistence observed in
the ancestor after 5 h treatment with amikacin (e) and ofloxacin (f) (mean ± s.e.m., n≥ 3). Significance of difference with ancestor: ***P < 0.001, ns, not
significant (ANOVA with Bonferroni post-hoc correction).
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experiments, we verified that clones display tolerance levels for ami-
kacin similar to those of the whole population, thereby ruling out
the presence of rare mutants inducing population-wide tolerance17
(Fig. 2a and Supplementary Fig. 1a). In addition, clones that
evolved on amikacin also showed increased cross-tolerance5 to the
aminoglycosides kanamycin, tobramycin and gentamicin
(Supplementary Fig. 1b–d) and the unrelated fluoroquinolone anti-
biotic ofloxacin (Fig. 2b and Supplementary Fig. 1e). Minimum
inhibitory concentrations (MICs), however, remained unchanged,
hence ruling out the presence of antibiotic resistance (Fig. 2c,d).
The increased survival may be explained in two ways: either all
cells increased their tolerance or the fraction of tolerant persister
cells increased. However, the killing dynamics of the evolved
clones are better described by means of a biphasic fit as opposed
to by a uniphasic fit, strongly supporting the hypothesis that it is
the persister level that has changed rather than the general popu-
lation-wide tolerance level (Fig. 2a,b and Supplementary Methods).
The fast and smooth sigmoidal increase in survival observed in
response to repeated antibiotic exposure corresponds to the
pattern expected for the spread of a single, highly beneficial
mutation in the population (Fig. 1b, equations 1–3 see
Supplementary Methods). Indeed, whole-genome sequencing of
seven evolved high-persistence clones confirmed that these clones
differed from the ancestor by only a single non-synonymous
mutation (Supplementary Table 1). We confirmed that these
mutations are causal to the extreme change as we could completely
restore the initial tolerance level by restoring the ancestral sequence
(Fig. 2e,f ). None of the genes in which mutations occurred have
previously been linked to persistence. Reductions in membrane
potential or translation activity limit antibiotic uptake and target
activity, respectively, and could explain the increased tolerance to
aminoglycosides18. However, this was only the case for translation
activity in one mutant (Supplementary Fig. 2). Also, further
increasing amikacin concentrations did not improve killing
(Supplementary Fig. 3a,f ). Direct head-to-head competition
experiments2,14 further confirmed the large fitness benefit of
the high-persistence mutants under frequent antibiotic exposure
(see Methods), with the high-persistence mutants having a
160–360-fold fitness advantage compared with the ancestor over a
single round of amikacin antibiotic treatment (Fig. 3a). By fitting
kinetic parameters of growth, killing and persistence in the ancestor
and the three high-persistence mutants (Supplementary Fig. 4 and
Supplementary Table 2, see Supplementary Methods), we inferred
that this fitness advantage is primarily caused by an ∼1,000-fold
increase in the rate of persister cell formation a during late exponen-
tial and early stationary phase. Results of a recent study showed the
development of tolerance through lag-time evolution16. However,
our evolved clones showed no increase in lag time following dilution
in fresh medium (Supplementary Figs 4 and 5a), which was not
unexpected as we added antibiotics at stationary phase as opposed
to stationary phase diluted in fresh medium16. There was,
however, evidence for additional, pleiotropically linked effects,
including a shortened lag phase following treatment (which is the
regular lag time plus the time needed to switch back from persister
to normal cell type), an earlier onset of persister formation during
growth after treatment and dilution in fresh medium and a larger
fraction of instantaneous awakening of persisters after treatment
and dilution in fresh medium (Supplementary Fig. 4 and
Supplementary Table 2). The shortened lag phase following treat-
ment was also confirmed by independent observations of a larger
set of evolved clones (Supplementary Fig. 5b). These results are
remarkable, as they show that minor genetic alterations can lead
to a plethora of adaptive changes in persister cell formation in
response to repeated antibiotic exposure.
If high persistence evolves so quickly and carries such a large
fitness advantage under conditions of frequent antibiotic exposure,
the question arises of whether the phenotype also carries a cost in
favourable growth conditions, and hence, if it is reversible. One
possible cost of persistence is a decreased growth rate, caused by
the fact that persisters do not divide8–10 although this has been
recently shown to be not necessarily the case19,20. Competition
experiments in the absence of antibiotic treatments, using the set-
up of the evolution experiment, identified a cost in the high-persist-
ence mutants in terms of a 1.36–1.95-fold decreased long-term
fitness compared with the ancestor (Fig. 3a). An interstrain compe-
tition model (model A, equation 6 see Supplementary Methods)
confirms that this cost was caused by a growth deficit linked to
the increased presence of non-growing persister cells
(Supplementary Fig. 6). Nevertheless, this cost is limited since pers-
isters are formed only very late in exponential phase
(Supplementary Fig. 4), which explains why the evolved clones
showed no systematic differences in their maximal growth rate in
exponential phase (Supplementary Fig. 5c). Overall the fitness
cost was, however, sufficient to lead to a slow decrease in tolerance
in a long-term evolution experiment in which high-persistence
mutant lineages were regrown daily in the absence of any antibiotic
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Figure 3 | Costs and benefits of persistence under contrasting levels of
antibiotic exposure. a, In competition experiments (see Methods), three
evolved high–persistence mutants (mutant*) had a two orders of
magnitude fitness advantage over the ancestor across a single round of
amikacin treatment (left), but a significantly reduced fitness across a single
dilution and regrowth cycle (right) (mean ± s.e.m., n = 3). Significance of
difference with control: **P < 0.01, ***P < 0.001 (ANOVA with Bonferroni
post-hoc correction). The control showed that fluorescent labelling did not
affect fitness (no significant deviation from 1, one-sample t-test).
b, The cost of persistence in the absence of antibiotic treatment results in
a slow reduction in persistence in an evolution experiment in which cultures
of three high–persistence mutants (mutant*) were regrown daily under
conditions without antibiotic treatments for 64 days (1,280 generations, see
Methods) (mean ± s.e.m., n≥ 3, exponential and linear fits for mutants and
ancestor control and 95% c.i. (shading); the slope for control was not
significantly different from zero, F-test, P = 0.48; significance of difference
between the end and starting levels or between the end levels and the level
of the control at the end: oppB* and gadC* ns, nuoN* P < 0.01, ANOVA with
Bonferroni post-hoc correction).
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treatments (Fig. 3b). Targeted sequencing of clones collected at the
endpoint of this experiment revealed that the original mutations
were still present and that the observed decreased tolerance
(Supplementary Fig. 7) was therefore due to compensatory
mutations as opposed to direct genetic reversions. The rate of rever-
sal back to original wild–type tolerance levels, however, did not cor-
relate with the mutants’ fitness cost (Fig. 3a). Combined with the
fact that some strains only showed a partial reversal, this hints at
constraints in their evolvability.
The variable costs and benefits of persistence as a function of the
prevailing antibiotic treatment schedule suggest that persistence
should quickly evolve to correlate with treatment frequency, akin to
models of persistence and bet-hedging, which predict that the
optimal allocation to non-growing persisters or other dormant life
stages should be inversely proportional to the duration of favourable
environmental conditions8–10,21–23. An evolutionarily stable strategy
model tailored to the specifics of our system confirms this prediction
(Fig. 4a, see Supplementary Methods), and evolution experiments
in which the antibiotic treatment interval was varied between 1 and
10 days showed that within just five cycles endpoint tolerance levels
indeed strongly correlated with antibiotic treatment frequency, as
well as with the theoretically expected evolutionary optimum
(Fig. 4b). The closest match between observed tolerance levels and
theoretically predicted values was found for treatment intervals of
between 1 and 4 days (Fig. 4b inset). For longer treatment intervals,
observed values were slightly below the predicted optimum, probably
because the long-term evolutionary equilibrium had not yet been
reached, something which was also apparent at the clonal level
(Supplementary Fig. 8a). Nevertheless, the biphasic killing behaviour
of clones with intermediate tolerance levels shows that it was mainly
the persister level that evolved, and that there was not just a gradual
increase in population-wide tolerance (Supplementary Fig. 8b).
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Figure 4 | Persister levels quickly adapt in response to the frequency of antibiotic treatment. a, A model parameterized with data from the ancestor
(Supplementary Fig. 4; equation 6 and model A in Supplementary Methods) clearly shows that more frequent antibiotic exposure selects for an increased
evolutionarily stable state (ESS) level of switching to the persister state, as predicted by bet-hedging theories8–10. In addition, a typical high-persistence
mutant (crosshair, aM = 0.5) is predicted to have a fitness advantage and be able to invade only under daily antibiotic treatments (left), but not when
treatment occurs every 5 days (right) (for comparison, see Supplementary Fig. 6). b, These predictions are supported by evolution experiments in which
populations were periodically exposed to amikacin every 1–10 days, and where after five rounds of selection, persister levels showed a clear correlation with
antibiotic treatment frequency (mean ± s.e.m., n≥ 3, sigmoidal fits and 95% c.i. (shading) derived from equations 1–3 in Supplementary Methods). Inset,
Comparison of observed persister plateau values (dots; plateau values of b) with expected ESS persister levels based on two model variants, model A
(continuous line), in which only switching rate a evolved, and model B (dashed line), where increased switching was linked with additional pleiotropic effects
(see Supplementary Methods).
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Overall, our findings are remarkable in showing that persistence
is a highly evolvable trait that quickly adapts to drug-treatment fre-
quency, and that its evolutionary dynamics can be understood in the
context of bet-hedging theory8–10,21–25. Worryingly, our results also
show that extremely high levels of persistence can emerge within
as little as two or three treatment cycles under conditions that
approximate the once-daily dosing of aminoglycosides in the
clinic26. Clearly, these findings worsen the already grim outlook of
the ongoing antibiotic crisis, and exacerbate the dangers of anti-
biotic misuse in medical settings1,27. Moreover, whereas traditional
antibiotic resistance is readily screened for using clinical diagnostic
methods and typically requires multiple mutations28,29, high-persist-
ence mutants are undetectable using standard practice and can be
caused by simple point mutations2,16. This makes persisters a prob-
able reservoir from which antibiotic resistant cells can emerge30 and
a drastically understudied cause of antibiotic therapy failure7. These
results should be a wake-up call to start widespread clinical testing
for antibiotic persistence and to begin the development of optimized
drug treatment regimens that minimize the emergence of antibiotic
tolerant persisters.
Methods
Bacterial strains and culture conditions. The two ancestor E. coli strains used in
this study are derived from BW25993 and identical except for the expression of
either Venus (SX25) or a Tsr-Venus (SX4) fusion from the lacZ locus31. The original
kanamycin resistance (KmR) cassette in both strains was removed by Flp–mediated
recombination32, yielding the SX25 and SX4 ancestral strains, which we refer to as
ancestor. Strains were grown at 37 °C in either Mueller Hinton Broth (MHB)
medium or on lysogeny broth (LB) agar plates.
Persistence assays. Survival following antibiotic treatment was determined in
stationary phase unless stated otherwise. Stationary phase was reached after
overnight growth, starting with a 1:100 dilution in 100 ml MHB of an initial
overnight culture. Serial dilution and plating were used to determine the number of
colony forming units (c.f.u.). The concentration of antibiotics used to quantify
persisters was defined as the concentration at which a plateau was reached in the
number of c.f.u. after a 5 h treatment (Supplementary Fig. 3). Antibiotics that were
used are amikacin (100 µg ml−1), kanamycin, gentamicin, tobramycin (all 400 µg ml−1)
and ofloxacin (20 µg ml−1). Evolution experiments performed over longer periods
would increase the probability of selecting for antibiotic-resistant mutants and
therefore in these experiments, 400 µg ml−1 amikacin was used to limit the selection
of resistance (Fig. 4b and Supplementary Fig. 8). Concentrations were at least
16 times the minimum inhibitory concentration (MIC) (Fig. 2c,d; 6.25, 8, 2, 4 and
0.08 µg ml−1 as determined via the microdilution method for respectively amikacin,
kanamycin, tobramycin, gentamicin and ofloxacin) and treatments were always
performed in 1 ml culture volumes. The percentage survival or persister level is the
ratio of the number of c.f.u. after treatment and the total number of c.f.u. before
treatment. Persister levels were logit transformed (logit(y) = ln(y/(1 − y)), with
y = survival proportion) to take into account the fact that these numbers are
bounded between 0 and 100% and in order to obtain normally distributed data
(verified using Kolmogorov–Smirnov tests). The significance of pairwise differences
between persister levels was determined using two–tailed t-tests, and using Welch’s
correction if variances were not equal (determined by F-tests). When the persister
levels of more than two strains were compared, ANOVA with post–hoc correction
was used. For visual clarity, inverse logits of the means in logit persister level ± s.e.m.
were displayed, although all statistics were performed on logit transformed data.
Evolution experiments. Parallel populations for the evolution experiments originated
from distinct single colonies of SX4 or SX25 cured of their KmR cassettes. In Fig. 1b and
Fig. 3b, odd populations were founded by SX4, even populations by SX25, in Fig. 4b all
populations were founded by SX25. Overnight batch growth to stationary phase in
100 ml of MHB was alternated with 5 h antibiotic treatments with either 1, 2, 4, 6, 8 or
10 days between treatments (indicated in the figures). Treatments were performed using
high antibiotic concentrations, eliminating all non-persister cells (see ‘Persistence assays’;
Supplementary Fig. 3) and during stationary phase, where active replication is low, to
limit selection for resistance. In addition, the stationary-growth phase is more related to
biofilms and chronic infections33. Aminoglycosides were used as these antibiotics can
kill non-growing, stationary-phase cells and display clear biphasic killing kinetics3,34,35.
Fluoroquinolones were avoided as they are known bacterial mutagens36,37 and prone to
cause fast development of resistance by single-target mutations38–40. After antibiotic
treatment, cells were washed three times in sterile 10 mMMgSO4 to remove antibiotics
and diluted 1:100 in 100 ml of fresh MHB for another round of overnight batch growth
to stationary phase. On days without antibiotic treatment, a 106-fold dilution was made
to initiate another growth round without antibiotic exposure, which yielded a
population bottleneck similar to dilution after the first antibiotic treatment. During the
experiment, we quantified persister levels by plating out before and after treatment.
At regular time intervals and at the end of the experiment, the fluorescence of the
Venus–tag from the ancestors was verified in populations and isolated clones to
rule out contaminations. The difference in fluorescence localization in the two ancestral
strains used allowed us to detect cross-contamination, which was never observed.
Numbers of generations given in the text are estimated values that are based on
the formula:
∑
n log2(c.f .u.f/c.f .u.i) (ref. 41), with c.f.u.f being the number
of c.f.u. at the end of the cycle and c.f.u.i the number of c.f.u. at the start and this
added together for n cycles.
Antibiotic sensitivity tests. MICs were quantified based on adaptations of methods
described elsewhere42,43. Briefly, an overnight culture was diluted in MHB to an
inoculum of 1 × 106 c.f.u.ml−1, incubated in a range of two-fold antibiotic dilutions and
grown for 16–20 h. This method is also known as the microdilution method. After
incubation, the A595nm was measured.We defined the MIC value as the lowest antibiotic
concentration where no growth was observed. For independent confirmation of MIC
values, the commercially available and clinically certified MIC test strips of Liofilchem
were used.
Whole-genome sequencing and identification of mutations. To identify
mutations arising in the high–persistence clones, whole-genome sequencing was
performed on an Illumina HiSeq 2000 (Illumina). Genomic DNA from the ancestor
and seven selected mutants was isolated from overnight cultures using the DNeasy
Blood and Tissue Kit (Qiagen). DNA purity and concentration was assessed by
Nanodrop analysis, gel electrophoresis and Qubit (Thermo Fisher); analysis.
Libraries were prepared with an average insert size of 200 bp and 100 bp paired–end
multiplex sequencing was performed either at the Genomics Core (University
Hospital UZ Leuven, Belgium) or at the EMBL Genomics Core Facility (Genecore;
Heidelberg, Germany), resulting in on average 12 million reads per sample. Analysis
was performed with Qiagen’s CLC GenomicsWorkbench version 6.0 or later (http://
www.clcbio.com/), and included standard quality control, read trimming and
filtering (41 nucleotides at 3′ end were removed, reads with less than 15 nucleotides
were discarded, quality score limit=0.01, ambiguous nucleotides trim limit=2), read
mapping to E. coliMG1655 reference (NCBI accession number NC_000913.2) using
default parameters (mismatch cost=2, insertion cost=3, deletion cost=3, length
fraction=0.8, similarity fraction=0.8) yielding on average a 150-fold genome
coverage. Lists of mutations were obtained using CLC’s variant detection tools and
were compared between ancestor and mutants. The found single-nucleotide
polymorphisms were verified by Sanger sequencing.
Repair of site-specific point mutations. The identified chromosomal point
mutations were repaired by P1vir phage transduction44. P1 lysates from yddW::KmR,
yfbP::KmR and cls::KmR Keio knockout mutants45 (BW25113 background, collection
numbers JW1486, JW2270, JW1241) were used to restore the gadC*, nuoN* and
oppB* alleles to the ancestral wild-type sequence, respectively. Restoration of site-
specific mutations was verified by Sanger sequencing and the KmR-cassette of
constructed strains was removed by Flp-mediated recombination before
determination of the tolerance level (Fig. 2e,f )32.
Measuring the membrane potential. Membrane potential was measured by
incubating stationary phase cultures for 10 min with 10 µg ml−1 bis-(1,3-
dibarbituric acid)-trimethine oxanol) [DiBAC4(3)], a membrane-potential-sensitive
dye, after which samples were analyzed for single-cell fluorescence with flow
cytometry (BD Influx, 488 nm excitation and emission through a 530/540 nm
bandpass filter). Controls were treated for 1 h with 500 µM carbonyl cyanide
m-chlorophenyl hydrazone before incubation with 10 µg ml−1 DiBAC4(3) and analysis.
Direct competition experiments. In order to perform direct competition
experiments, non-fluorescent variants of ancestors and evolved mutants were
generated by P1vir transduction44 using the lacI::KmR Keio mutant (BW25113
background, collection number JW0336)45. After transduction, the KmR-cassette
from a non-fluorescent colony was removed using Flp-mediated recombination32.
Prior to the competition experiment, overnight cultures were diluted to an A595nm of
0.5. Equal volumes of a fluorescent and non-fluorescent strain were mixed and
diluted 1:100 in MHB for overnight growth to stationary phase. The 50/50 ratio was
verified by microscopy on an Axio Imager.Z1 fluorescence microscope (Carl Zeiss).
To measure relative fitness, the mixed culture was subjected to one round of
antibiotic treatment and subsequent regrowth to stationary phase or three rounds of
growth in fresh medium without intermittent antibiotic treatment (as described in
‘Evolution experiments’). At least three microscopic images per culture were taken
daily, containing in total between 250 and 2,250 cells. The relative contribution of
each competing strain was determined by counting the number of fluorescent and
non-fluorescent cells using the analysis toolkit of the Zen Blue software (Zeiss).
Relative fitness was calculated based on the discrete time recurrence equation for
selection in a haploid population46 (equation 2 see Supplementary Methods), as it
enables relative fitness WA over a single round of selection to be solved based on the
difference between the final observed proportion of mutants p(t) compared with the
initial proportion p(0), given a certain number of selection rounds T used (one in
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the presence of antibiotics, three in their absence, Fig. 3a). Relative fitness was
compared with the control using ANOVA with post-hoc correction, in case of the
mutants, and for the control (comparing the ancestor to itself ) to a value of 1,
expected in the absence of any selective advantage, in order to confirm marker
neutrality, using one sample t-tests.
Assessment of translation activity in stationary phase. To assess translation
activity in stationary phase, non-fluorescent variants of ancestors and evolved
mutants were transformed with pDiGc (ref. 47), a plasmid containing genes for a
constitutive GFP expression and an arabinose-inducible DsRed. After 16 h of
growth, stationary phase cells were induced with 0.2% arabinose and fluorescence
was monitored over time with a Synergy2 multimode reader (BioTek excitation:
540 nm, emission 590 nm). Controls were non-induced samples and induced
samples treated with 50 µg ml−1 chloramphenicol to block translation.
Normalization was performed to obtain arbitrary fluorescence units (divided by
the GFP fluorescence per sample and subtracted with the DsRed fluorescence of
non-induced chloramphenicol treated samples).
Determination of growth rate and single-cell lag time. Growth characteristics of
the selected mutants were measured with a Bioscreen C incubator with automatic
A600nm plate readings every 15 min (Bioscreen C, Oy Growth Curves, http://www.
bioscreen.fi/). Wells with the highest dilution still displaying growth, with at least two
subsequent dilution steps without growth, were selected for single-cell lag time
calculation given the high chance that they emerged from single cells48. The slope of
the linear part of the log10(A600nm) curve as a function of time yielded doubling time
by the equation: doubling time = log(2)/slope. Lag times were calculated as the
intersection of the slope curve with the initial A600nm value. Statistical significance of
differences was determined with ANOVA with post-hoc correction.
Accession numbers. Sequence data are available in the SRA repository of NCBI
(SRP051150).
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Supplementary Figure 1. Clones evolved on amikacin show increased cross-tolerance to 
other antibiotics. Clones randomly selected from populations exposed to daily amikacin 
treatments at the endpoint of the evolution experiment (see Fig. 1b, red) showed significantly 
increased tolerance to a, amikacin (cf. Fig. 2a) and cross-tolerance to b, kanamycin, c, 
tobramycin, d, gentamicin and e, ofloxacin (cf. Fig. 2b) (mean±s.e.m, n≥3). Clone name 
indicates population of origin (first number; all originating from the first population are in red, 
from the second in yellow and from the others in orange) and replica clone within the population 
(second number). Significances of differences with ancestor: *P<0.001, **P<0.001, 
***P<0.001, ns, not significant (ANOVA with Bonferroni post-hoc correction). Clones were 
sorted based on their amikacin persister level to show the correlation with the level of 
persistence after kanamycin treatment (Spearman rank R=0.89, P=0.000001). Correlations with 
persistence to tobramycin (R=0.33, P=0.18), gentamicin (R=0.43, P=0.078) and ofloxacin 
(R=0.23, P=0.35) were less strong and not significant, even though persister levels were 
generally still much higher than ancestor levels. 
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Supplementary Figure 2. Reduced membrane potential or translation activity cannot fully 
explain the increased tolerance in three evolved high-persistence mutants. a, The 
membrane potential of three evolved high-persistence mutants was not lower than in the 
ancestor. Histograms show the single-cell fluorescence distribution after incubation with 
DiBAC4(3), a potential-sensitive dye that can only enter depolarized cells, as is evident from 
the increased fluorescence in the control samples (filled histograms) that have been treated with 
the protonophore carbonyl cyanide m-chlorophenyl hydrazine (CCCP) (representative 
histograms are shown of n=2). b, Translation activity in stationary phase was assayed in all 
three evolved high-persistence mutants by induction of DsRed from a plasmid. Except for the 
oppB* mutant, no differences were observed between the evolved high-persistence mutants and 
the ancestor (mean±s.e.m., n=3 with exponential (induced) or linear (controls with 
chloramphenicol) fit and 95% c.i. (shade) with a.u., arbitrary units), indicating that stationary-
phase translation was unaffected. Significances of differences with ancestor: ***P<0.001 
(repeated measures ANOVA with Bonferroni post-hoc correction).  
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Supplementary Figure 3. Killing curves in function of concentration using several 
antibiotics reveal the presence of a typical persister plateau. a, A stationary-phase culture 
was treated with different concentrations of amikacin, b, kanamycin, c, tobramycin, d, 
gentamicin or e, ofloxacin for 5 h to reveal the typical expected plateau of decreased efficiency5 
(mean±s.e.m., n≥3). For comparison, in a, data for the three evolved high-persistence mutants 
were added to show that simply increasing amikacin concentrations does not increase killing. 
f, Clones selected from populations exposed to daily amikacin treatments at the endpoint of the 
evolution experiment (see Fig. 1b, red) still showed significantly increased tolerance to 
amikacin when the concentration was increased to 1000 µg ml-1. Significances of differences 
with ancestor: ***P<0.001 (ANOVA with Dunnett post-hoc correction). 
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Supplementary Figure 4. Dynamics of growth, persister cell formation and killing during 
antibiotic treatment in the ancestor and two evolved high-persistence mutants. Dynamics 
of growth and persister cell formation (blue shading, left), killing during amikacin antibiotic 
6 NATURE MICROBIOLOGY | www.nature.com/naturemicrobiology
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treatment (red shading, middle) and regrowth of persisters (blue shading, right) after 100-fold 
dilution (marked with D) in three evolved high-persistence mutants (Supplementary Table 1, 
n=3 each) and the ancestor (pooled data from 2 populations, n=3 each) shown with a best fit to 
differential equation system Eq. 5 (cf. parameters in Supplementary Table 2, see Supplementary 
Methods). The fitness benefit of high-persistence mutants is mostly linked to a ca. 1,000-fold 
increase in the rate of switching to the persister state a during late exponential and early 
stationary growth. Furthermore, there was evidence for pleiotropically linked effects in the 
high-persistence mutants, including a reduced growth lag λtn after antibiotic treatment (cf. 
Supplementary Fig. 5b), an earlier onset of persister formation during growth after treatment 
and dilution in fresh medium λpft and an increased fraction of persisters that awaken 
instantaneously fat (Supplementary Table 2).  
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Supplementary Figure 5. Single-cell growth parameters in evolved high-persistence 
clones. a, Single cells of high-persistence clones from populations evolved on amikacin 
(Fig. 1b, red) show similar lag times after dilution compared to the ancestor (analogous to 
parameter λdn in Supplementary Table 2). b, Persister cells of high-persistence clones show 
reduced growth lag after antibiotic treatment at the single-cell level compared to persister cells 
of the ancestor (analogous to parameter λtn in Supplementary Table 2). c, High-persistence 
clones show no consistent change in doubling times compared to the doubling time of the 
ancestor (analogous to parameter µgn in Supplementary Table 2). These figures were based on 
single-cell founded optical density growth curves, and used a different set-up than that used for 
Supplementary Fig. 4 (see Methods, explaining the difference in absolute numbers between 
values reported here and λdn, λtn and µgn in Supplementary Table 2). Numbers show mean lag 
times (vertical lines±s.e.m., n≥3). Clone name indicates population of origin (first number) and 
replica clone within the population (second number). Significances of differences with ancestor: 
*P<0.05, **P<0.01, ***P<0.001, ns, not significant (ANOVA with Dunnett post-hoc 
correction). 
  
8 NATURE MICROBIOLOGY | www.nature.com/naturemicrobiology
SUPPLEMENTARY INFORMATION DOI: 10.1038/NMICROBIOL.2016.20
 
Supplementary Figure 6. Selective advantage of high-persistence mutants and 
evolutionarily stable levels of switching to the persister state as a function of antibiotic 
treatment interval. Pairwise invasibility plots46,49,50 showing the invasion potential and 
selective advantage of rare mutants that switch to the persister state with rate aM (per h) in a 
wild-type resident population where cells switch with rate aW (per h). Plots were calculated 
from Eqs. 6, 7 using the best-fit parameters of Supplementary Table 2 under two model variants: 
model A (top), in which only the switching rate a evolved, and model B (bottom), where 
increased switching was linked with additional pleiotropic effects. Under model A, a typical 
high-persistence mutant with switching rate aM=0.5 (crosshair) could invade in a population 
with observed wild-type ancestor rate of switching aW=0.0005 if antibiotic treatment was 
administered once a day (left), but not if it was administered once every 5 or 10 days (middle 
and right). Taking into account the possibility of other linked pleiotropic effects (bottom, see 
supplementary methods), the high persistence mutant would still be able to invade in a situation 
with antibiotic treatments once every 5 days, but not with treatments administered once every 
10 days. Under both models, the evolutionarily stable (ESS) level of switching to the persister 
NATURE MICROBIOLOGY | www.nature.com/naturemicrobiology 9
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state is higher with increased frequencies of antibiotic exposure, but slightly more so if 
persistence has additional linked pleiotropic effects (bottom). In the absence of antibiotic 
exposure, models A and B predict that a high-persistence mutant with aM=0.5 would have a 4.3 
and 4.5-fold fitness disadvantage relative to the ancestor over a single dilution and growth cycle, 
respectively. 
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Supplementary Figure 7. Evolution in the absence of antibiotic treatments reverses high 
tolerance of high-persistence mutants on clonal level. Evolution without treatment decreases 
persistence at the population level (Fig. 3b). a, Persister levels after 5 h treatment with amikacin, 
b, kanamycin or c, ofloxacin for the ancestor, the high-persistence mutant at the start (mutant*) 
and five random clones at the end of evolution without treatment in Fig. 3b (mutant*-1 to 5) 
show that the decreased tolerance is also present on the clonal level (mean±s.e.m., n≥3). 
Significance of difference with original mutants (for reversed clones mutant*-1 to 5) or ancestor 
NATURE MICROBIOLOGY | www.nature.com/naturemicrobiology 11
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(for control clones 1 to 5): **P<0.01, ***P<0.001, ns, not significant (ANOVA with 
Bonferroni post-hoc correction). 
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Supplementary Figure 8. Persister level in relation to treatment frequency at the clonal 
level.  a, Survival levels after 5 h treatment with amikacin for randomly selected clones (≥9) at 
the endpoint of each population in Fig. 4b correlate with treatment frequency (mean±s.e.m., 
n≥3, violin plots show the probability density of the data). Solid line shows a linear fit on a logit 
scale ± 95% c.i. (shade). For longer treatment intervals (8 and 10 days), it is apparent that 
evolution has not yet reached its final optimum, which may explain why for those treatment 
intervals, the observed survival levels deviate further from the predicted evolutionary optimum 
(cf. Fig. 4b inset). b, Amikacin killing curves in function of time for 3 representative clones 
from populations evolved under amikacin exposure once every 6, 8 or 10 days, the ancestor and 
11 clones evolved under daily amikacin treatment (replicated from Fig. 2a for comparison) 
show clear biphasic behavior - the hallmark for the presence of a persistent, antibiotic-tolerant 
subpopulation (mean±s.e.m., n≥3 with the per-treatment biphasic fit (thick lines) expected for 
the killing of a population containing a subpopulation of normal and persister cells 
superimposed, see Supplementary Methods). 
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Supplementary Table 1. Mutations detected in seven clones by whole genome sequencing. 
 
*Clones were randomly selected at the endpoint of the evolution experiment (Fig. 1b, red). 
Clone name indicates population of origin (first number) and replica clone within the population 
(second number). 
†These mutants were selected for further analysis in Figs. 2, 3, Supplementary Figs. 2-5, 7 and 
Supplementary Table 2. 
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Supplementary Table 2. Best-fit growth, killing and persister formation parameters of the 
ancestor and two derived high-persistence mutants. 
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Parameters were fitted using Mathematica v10 based on the differential equation system given 
in Eq. 5 (see Methods), using OLS regression on a log10(y+1) scale and empirical time series 
of persister cell formation and total cell numbers (CFU ml-1) observed during a 12 h growth 
period followed by 5 h amikacin treatment at 19 h and a further 12 h regrowth period for the 
ancestor populations 1 and 2 and high-persistence mutants oppB*, nuouN* and gadC* (clones 
1-1, 2-1 and 6-1) (n=3 replicates for each of the ancestor populations and each of the mutants). 
Actual fits are shown in Supplementary Fig. 4. Both 95% confidence limits and significance of 
the difference with the parameter values in the ancestor (based on the 3 replicate values of the 
mutants and calculated using a two-tailed one-sample t-tests) were calculated on a log10 scale 
for λtn, λpfd, λpft and µtp (as these parameters are strictly positive), and on a logit scale for fat (as 
this parameter is constrained between 0 and 1), and were for the confidence limits then 
backtransformed to the original scale. 
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Supplementary Methods 
1. Fitting of evolutionary trajectories 
Data in Fig. 1b and Fig. 4b were fitted based on the discrete-time recurrence equation describing 
the spread of a mutant in a haploid population46: 
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where WA is the fitness of mutant strain A relative to ancestral strain a and p(T) and q(T) are the 
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If the phenotype of the ancestor is z and that of the mutant is Z, we can see that the average 
phenotype P(T) of the population would evolve according to the equation: 
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where s is the selective advantage of the mutant A (WA-1). For the data shown in Fig. 1b, 
observed logit transformed persister levels were fitted to Eq. 3 using Mathematica v10 with the 
function NonlinearModelFit. Hence, z and Z should be interpreted as the logit transformed 
persister proportions in the ancestor and mutant (after the mutant went to fixation). This resulted 
in best-fit parameters for amikacin: p(0)=0.0005, z=-6.43 (i.e. initial proportion of 
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persisters=0.16%), Z=0.46 (i.e. final average proportion of persisters=61.29%) and s=19.6; for 
kanamycin: p(0)=0.002, z=-9.59, Z=0.88 and s=12.9; for tobramycin: p(0)=0.002, z=-10.64, 
Z=-0.07 and s=12.1; for gentamicin: p(0)=0.0001, z=-11.21, Z=-2.57 and s=30.8. An alternative 
model in which replicate-specific values for Z were used was also tested but found to result in 
a lower overall goodness of fit (higher Akaike Information Criterion). For the evolution 
experiment shown in Fig. 4b, we took advantage of the fact that the final logit transformed 
persister level showed a near-linear relationship with the interval between antibiotic treatments. 
Hence, in this case we fitted Eq. 3 but using Z=c-dxtg, where tg was the interval between 
antibiotic treatments in days. Again, alternative models were tested, e.g. incorporating treatment 
and/or replicate-specific values for Z, but all were found to result in a worse overall model fit 
(higher Akaike Information Criterion), and so were not further pursued. Best-fit parameters for 
the best model (Fig. 4b) were p(0)=0.0005, z=-8.00, c=2.17, d=0.64 and s=19.3. For the reversal 
of persistence in the absence of antibiotic treatment (Fig. 3b), data from the population 
originated from the oppB*, gadC* and nuoN* mutants were fitted using the exponential 
equations: 8.034-809.9
1582.0 xey ×−×= , 6.341-125.6
0739.0 xey ×−×=  and 
6.533-221.6 01769.0 xey ×−×= , whereas the control condition was fitted using a straight line, 
xy ×+−= 004162.0055.8  (slope not significantly different from 0, F-test, P=0.4813). Again, 
alternative equations were tested, e.g. polynomials and/or straight lines, but all were found to 
result in a worse overall model fit (higher Akaike Information Criterion), and so were not 
further pursued. We should note that neither in Fig. 3b nor in 4b, perfect fits were expected. For 
example, in the experiments shown in Fig. 4b, it was likely that not just one but diverse mutants 
actually competed with the ancestor, and that mutants accumulated multiple mutations. For 
example, the observed deviations from the curve predicted based on the invasion of a single 
mutant has the form of a damped oscillation. This suggest that initially, mutants with a very 
high persister level spread through the population, thereby causing the phenotype to 
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“overshoot” the fitting, and that this overshoot was only corrected through the subsequent 
invasion of mutants with lower persister levels. Similarly, for the results shown in Fig. 3b, the 
considered time period was very long and clearly comprised repeated mutations. This complex, 
stochastic process was simply approximated by a purely phenomenological and deterministic 
exponential model.  
2. Fitting of killing curves 
To describe the dynamics of killing curves, data in Fig. 2a, b and Supplementary Fig. 8 were 
fitted based on the following biphasic exponential killing equation: 
)(exp)(exp)( 00 TmPTmNTy pn ×−×+×−×=     (4) 
where y is the total viable cell number at time T, N0 and P0 are the number of normal and 
persister cells at the start, and mn and mp are the killing rates of normal and persister cells. 
Subsequently, Eq. (4) was normalized relative to the initial number of cells at the start (N0 + 
P0) to yield proportions of surviving cells and log10-transformed. To get initial parameter 
estimates, log-transformed survival proportions for each of five treatments (i.e. ancestor and 
evolved populations that had been treated every 1, 6, 8 and 10 days) were fitted using nonlinear 
least squares using the nls function in R. Subsequently, these initial parameters were used as 
starting values in a nonlinear mixed model fit, obtained using the function nlmer in the R nmle 
package. In this fit, we used treatment-specific estimates for the proportion of persisters at the 
start p0 and the mortality rate of persisters mp, but a single estimate for the mortality rate of 
normal cells mn, as this model resulted in the most parsimonious fit (based on the AIC). In 
addition, we included random uncorrelated variation across strains and across replicates within 
strains for parameters p0, mp and mn. These nls and nlmer fits were performed separately for the 
amikacin and ofloxacin killing curves.  
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All parameters differed significantly between the evolved clones and ancestor (all P<0.05), 
except for the persister mortality rate mp which for the amikacin treatment was not significantly 
different between the ancestor and the 1 and 6 day treatment-interval clones. The mortality rate 
of persister cells, mp, during ofloxacin treatment was significantly negative (i.e. the plateau in 
Fig. 2b rises significantly), even though per clone, points from 1 h onwards were not 
significantly different from each other for 7/11 clones (repeated measures ANOVA with 
Bonferroni post-hoc correction). The biological significance, however, of this slight increase 
remains uncertain. Growth is very unlikely, given that the used ofloxacin concentration was 
250-fold higher than the MIC and the MIC over 20 h of incubation did not show any increase 
in the evolved mutants (Fig. 2d). A temporary non-culturability of some of the viable persister 
cells, however, is one potential explanation for the small increase.  
The superiority of a biphasic model over a uniphasic model to describe the dynamics of killing 
was confirmed using likelihood ratio tests and comparison of AIC values of biphasic vs. 
uniphasic nonlinear mixed model fits for each of the treatments (Eq. 4 with P0 = 0; all  
P≤1e-14). Likelihood ratio testing is appropriate as the models are nested: the uniphasic model 
is a special, simplified case of the biphasic model (with the initial proportion of persisters set 
to 0). AIC includes a penalty that increases with the number of parameters,  and as such corrects 
for the fact that more complex models are intrinsically expected to have a better goodness of 
fit. The quality of the fits and the discriminating power of the model comparisons were 
enhanced by the use of non-linear mixed models, which fitted all replicate curves 
simultaneously, thereby resulting in a decreased sensitivity to noise in the data and in more 
powerful model comparisons. Hence, we conclude that a change in persistence was responsible 
for the improved survival rather than a general increased tolerance of all cells. As before, these 
calculations were performed using the nlme function nlmer in R (code available on request). 
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3. Fitting of kinetic parameters of growth, killing and persistence  
To be able to look at the detailed dynamics of growth, killing and persistence across a growth, 
treatment, and regrowth cycle in the ancestor and the high-persistence mutants, we determined 
the growth curve and formation of persister cells during growth, the biphasic killing curve upon 
exposure to amikacin as well as the regrowth curve and formation of persisters observed after 
treatment (Supplementary Fig. 4), and estimated growth and mortality parameters as well as 
phenotypic switching rates between normal and persister cells using a differential equation 
system (see below). To determine the growth curve and persister formation during growth, an 
overnight culture was diluted 1:100 in 100 ml MHB, incubated and sampled at one hourly 
intervals to determine the number of persister cells and the number of total cells (Supplementary 
Fig. 4). Persister numbers were estimated by treating the sample with amikacin for 5 h following 
three washing steps in sterile 10 mM MgSO4. Serial dilution and plating was used to determine 
the number of CFU. After 19 h and upon reaching stationary phase, serial dilution and plating 
on the last treated sample was performed at 1, 3 and 5 h after treatment to generate a killing 
curve in function of time. Finally, after 5 h treatment, the regrowth curve was determined by 
washing samples three times in sterile 10 mM MgSO4, diluting the culture 1:100 in 100 ml of 
fresh MHB (Supplementary Fig. 4) and incubating it, after which samples were taken every 
hour to again determine the number of persister cells and total number of cells by plating until 
cultures reached stationary phase.  
Subsequently, to deduce kinetic parameters of growth, killing and persistence (Supplementary 
Fig. 4 and Supplementary Table 2), observed numbers of normal and persister cells ( )tn  and 
( )tp  across one growth, treatment and regrowth cycle were fitted against the dynamics expected 
from the time-switched differential equation system: 
( ) ( ) ( ) ( ) ( ) ( ) ( )
( ) ( ) ( ) ( ) ( ) ( ) ( )tptbtntatptµtp
tptbtntatntµtn
p
n
×−×+×=
×+×−×=
'
'
     (5) 
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where ( )tµn  and ( )tµp  represent the time-specific growth or mortality of normal and persister 
cells and ( )ta  and ( )tb  are time-specific switching rates to the persister and normal cell states10. 
We further set: 
( ) ( ) ( )⎟⎠
⎞⎜⎝
⎛
−×=
K
tNtµtµ gnn 1  during growth, with ( ) ( ) ( )tptntN +=  being total population size, 
( ) gngn µtµ =  after lag tndn λλ or   following redilution or treatment and ( ) 0=tµn  before the lags 
to specify delayed logistic growth; 
( ) tnn µtµ −=  during treatment (killing of normal cells); 
( ) tpp µtµ −=  during treatment (low rate of killing of persister cells), ( ) 0=tµp  otherwise; 
( ) btb =  during growth following redilution or treatment, ( ) 0=tb  otherwise; 
( ) ( )pfDtSe
ata λ−×−
+
=
1
 during growth to specify a delayed sigmoidal increase with sharpness S 
in the rate of switching to the persister state to a maximum of a, with pfλ  and tD being the time 
lag and time since the last dilution and with pfdpf λλ =  after a simple dilution and pftpf λλ =  
after treatment and dilution, ( ) 0=ta  otherwise; 
( ) 00 nn =  = initial number of normal antibiotic-sensitive cells per ml = K/100; and 
( ) 00 pp =  = initial number of persister cells per ml (was assigned an arbitrarily low number of 
0.1 ml-1). 
Growth and dilution cycles of 24 h each could be iterated a number of times corresponding with 
a total length of good growth conditions tg and were alternated with a treatment cycle of length 
ts (= 5 h). After treatment, a 100-fold dilution was applied ( ( ) ( ) ( ) ( ) 100   ,100 tntntptp →→ ) 
whereas after redilution a 1,000,000-fold dilution was applied  
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( ( ) ( ) ( ) ( ) 66 10   ,10 tntntptp →→ ). Upon growth after dilution, persister cells were made to 
wake up near-instantaneously, since no persister could be observed during the first few hours 
of growth (Supplementary Fig. 4), and the fraction of persisters that awakened near-
instantaneously after treatment was captured by a parameter fat 
( ( ) ( ) 100/*)() /100,)1(*)()( atat ftpn(t n(t)ftptp +→−→ ). Switching in this model was 
assumed to stop during treatment, but predictions were virtually identical if this assumption 
was relaxed. Subsequently, all parameters were fitted using data from the two ancestor 
populations (n=3 replicates for each) as well as data from the oppB*, nuoN* and gadC* high-
persistence mutants (clones 1-1, 2-1 and 6-1, Supplementary Table 1, n=3 replicates for each). 
This was done using OLS regression on a log10(y+1) scale to minimize the total squared 
difference between log transformed observed and predicted total, persister and normal cells 
during growth, killing and regrowth. These calculations were done using Mathematica v10, 
using single parameter estimates for K, gnµ , tnµ , dnλ , S, and b (resulting in estimates for each 
of these parameters that were shared by all strains) and strain-specific parameters for a, tnλ , 
pftpfd λλ   , , tpµ , and fat (resulting in specific estimates of each of these parameters for each of 
the ancestor and high-persistence mutants) (Supplementary Table 2). The strategy that was 
followed here was that we aimed for the best overall fit (as measured by the Akaike Information 
Criterion) whilst keeping as many parameters identical between the ancestors and high-
persistence mutants (as they differed by only a single point mutation from the ancestor). 
Subsequently, 95% c.i. of all parameters were calculated based on the 3 replicate values of the 
mutants (Supplementary Table 2). As there were no significant differences in the parameter 
estimates for the two ancestor populations, this data was pooled to calculate overall average 
ancestor parameter values (Supplementary Table 2 and Supplementary Fig. 4). The principal 
difference between the high-persistence strains and ancestors was a ca. 1,000-fold higher 
maximal rate of switching to the persister state a (Supplementary Table 2 and Supplementary 
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Fig. 4), but there was also evidence for additional pleiotropically linked effects, including a 
reduced growth lag tnλ  after antibiotic treatment (best-fit relationship: 
( ) )(log1771.00455.0log 1010 atn ×−−=λ , Pearson R=-0.86 and P=0.14, see also 
Supplementary Fig. 5b), an earlier onset of persister formation within the growth cycle 
following treatment and dilution in fresh medium, pftλ  (best-fit relationship: 
( ) )(log0558.08221.0log 1010 apft ×−=λ , Spearman rank R=-0.98 and P=0.018) and an 
increased fraction of persisters that awakened instantaneously following treatment and dilution 
in fresh medium, atf  (best-fit relationship: )(log8974.09531.5)1(log 1010 afat ×−−=− ) (all 
across the 2 ancestor populations and 3 mutants; Supplementary Table 2). Another study 
recently found that increased persistence was linked to a delayed awakening of cells following 
dilution in fresh medium16. In our experiments, this trend was not observed, as all cells showed 
nearly instantaneous wake-up (Supplementary Figs. 4, 5). In addition, in our experiments 
treatment occurred in stationary phase as opposed to stationary phase diluted in fresh medium 
in ref. 16, thereby nullifying any selective benefits of delayed awakening in our set-up.  
4. Evolutionary model 
To determine the expected selective advantage of a high-persistence mutant subjected to a 
particular frequency of antibiotic treatment, or its selective disadvantage under good growth 
conditions, as well as to determine the expected evolutionarily stable (ESS) rate of switching 
to the persister state and the corresponding ESS level of persistence, we used a differential 
equation system equivalent to Eq. 5 but allowed competition between a wild-type and mutant 
strain with different rates of switching to the persister state a and, possibly, other growth 
parameters being pleiotropically linked to this: 
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( ) ( ) ( ) ( ) ( ) ( ) ( )
( ) ( ) ( ) ( ) ( ) ( ) ( )
( ) ( ) ( ) ( ) ( ) ( ) ( )
( ) ( ) ( ) ( ) ( ) ( ) ( )tptbtntatptµtp
tptbtntatntµtn
tptbtntatptµtp
tptbtntatntµtn
MMMMpM
MMMMnM
WWWWpW
WWWWnW
×−×+×=
×+×−×=
×−×+×=
×+×−×=
'
'
'
'
   (6) 
where W and M denote subscripts for wild-type and mutant-specific parameter values.  
In a first version of this model (model A), only the maximal rate of switching to the persister 
state was allowed to be different between the mutant and wild-type (specified using parameters 
aW and aM), whereas all other parameters were kept identical between both strains. This was 
consistent with parameter a showing the largest change in our evolution experiments and being 
the principal parameter that was subject to evolution. In a second model (model B), however, 
we also allowed changes in the rate of switching a to be pleiotropically linked to cause a reduced 
growth lag tnλ  after antibiotic treatment (using the best-fit relationship mentioned above: 
( ) )(log1771.00455.0log 1010 atn ×−−=λ , see also Supplementary Fig. 5b), an earlier onset of 
persister formation within the growth cycle following treatment and dilution in fresh medium, 
pftλ  (best-fit relationship: ( ) )(log0558.08221.0log 1010 apft ×−=λ , cf. above) and an increased 
fraction of persisters that awakened instantaneously following treatment and dilution in fresh 
medium, atf  (best-fit relationship: )(log8974.09531.5)1(log 1010 afat ×−−=− ). Earlier, 
evidence for such pleiotropy, including a reduced growth lag tnλ  after antibiotic treatment, was 
also found in Pseudomonas aeruginosa14, although that study also documented an increased lag 
phase in high-persistence strains following dilution, which was not observed in our E. coli 
strains. 
Other aspects of the model were set analogously as in Eq. 5, but with total population size ( )tN  
now equal to ( ) ( ) ( ) ( )tptntptn MMWW +++  and with the proportion of the mutant strain 
( ) ( ) ( )( ) ( )tNtptntP MMM +=  initially being set to an arbitrarily low value of 1/K to be able to 
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model the invasion potential of a rare mutant in the population46,49,50. Subsequently, invasion 
fitness, i.e. the long-term relative fitness of the mutant relative to the wild-type, under 
contrasting antibiotic treatment frequencies, was calculated from Eq. 2 as: 
( ) ( )( )
( ) ( )( )211
112
tPtP
tPtP
MM
MM
−×
−×         (7) 
where t1 and t2 represent the time at which stationary phase was reached during the first growth 
cycle before and after one antibiotic treatment episode (in case relative fitness was calculated 
under different antibiotic treatment frequencies) or before and after one growth and regrowth 
cycle (in case relative fitness was calculated in the absence of antibiotic treatment). In terms of 
definition, Eq. 7 therefore corresponds directly to the relative fitness calculations performed in 
our head-to-head competition experiments, but with the difference that the mutant here is taken 
to be initially rare, whereas in the competition experiments a 50:50 initial mix of mutant and 
ancestor cells was used. Mathematically, it is also equivalent to the geometric mean relative 
fitness of the mutant across time46,49.  
From differential equation system Eq. 6, we subsequently produced so-called pairwise 
invasibility plots46,49,50, in which the invasion potential and selective advantage of rare mutants 
with different rates of switching to the persister state aM are shown when they would emerge in 
wild-type populations with switching rate aW. Finally, the ESS maximum rate of switching to 
the persister state a* under a given antibiotic treatment frequency and the corresponding ESS 
persister level was calculated by checking which wild-type rate of switching to the persister 
state aW would be immune to invasion by a mutant that had a slightly higher rate of switching 
aW' (set by us at a value that was 0.01% higher than the wild-type value aW), and what persister 
level this would result in based on our differential equation system (Eq. 5) and our best-fit 
ancestor parameters (Supplementary Table 2). These ESS calculations were performed both for 
model A, in which only parameter a was allowed to evolve and the other parameters were set 
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to the best-fit mean ancestor value (Supplementary Table 2) as well as for model B, in which 
the growth lag after treatment tnλ , the earlier persister formation during growth following 
treatment and dilution in fresh medium pftλ , and the fraction of instantaneous awakening of 
persisters after treatment and dilution in fresh medium fat, showed pleiotropic changes with a 
(Fig. 4 and Supplementary Fig. 6). Given that no exact analytical solution for the ESS exists 
given our complex time-switched differential equation system, all these calculations were 
performed numerically using Mathematica v10 (code available on request). The numerically 
obtained ESS level of persistence in stationary phase in our model A, however, could be closely 
approximated by: 
bT
T
ba
a
g
g
+
=
+ 1
1
*
*         (8) 
where a* / ( a* + b) is the expected proportion of persisters in stationary phase10 given an 
optimal rate of switching from normal to persister cells a* and an observed rate of switching 
from persister to normal cells b (Supplementary Table 2). Under exponential growth, the 
optimal switching rate a* has been shown to be approximately equal to 1/Tg8,14, where Tg is the 
average length of good growth conditions, but which in our case should be counted to only 
include the fraction of the growth periods during which cells were actually growing (i.e. had 
not reached stationary phase) and during which persisters were formed, as this was the part of 
the growth cycle where persistence had a cost (in our case ca. 3.5 h out of each 24 h growth 
cycle, Supplementary Fig. 4). This shows the clear relationship of our numerical results to 
previous models of persistence and bet-hedging, which have consistently found that allocation 
to non-growing persisters or other dormant life stages should be inversely proportional to the 
duration of favourable environmental conditions8,9,14,21,25,49,51,52. Incorporation of additional 
pleiotropically linked effects of persistence in our model variant B slightly increases the 
expected ESS level of persistence (Fig. 4a and Supplementary Fig. 6).  
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